Patent · US Active

Use of SFRP-3 in the assessment of heart failure

US8691587B2 · kind B2 · utility

6Cited by

4References

19Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Ursula-Henrike Wienhues-Thelen · Krailling, DE
Sara Arab · Toronto, CA
Dirk Block · Bichl, DE
Andrew Emili · Needham, US
Anthony Gramolini · Toronto, CA
Georg Hess · Mainz, DE
Hendrik Heudig · Penzberg, DE
Peter Liu · Toronto, CA
David MacLennan · Toronto, CA

Key dates

Filing date	Oct 11, 2010
Grant date	Apr 8, 2014
Priority date	—
Expiry date	Apr 20, 2032

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/325
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.